Published in J Hepatol on April 18, 2013
Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol (2014) 1.66
Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol (2014) 1.06
Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05
Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways. J Transl Med (2013) 1.02
Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol (2015) 0.98
Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World J Gastroenterol (2013) 0.96
Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives. World J Hepatol (2015) 0.91
Value of radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Gastroenterol (2014) 0.87
Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res (2015) 0.87
Minimally invasive surgery versus percutaneous radio frequency ablation for the treatment of single small (≤3 cm) hepatocellular carcinoma: a case-control study. Surg Endosc (2015) 0.85
Echinococcosis: An Economic Evaluation of a Veterinary Public Health Intervention in Rural Canada. PLoS Negl Trop Dis (2015) 0.83
Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. Oncotarget (2016) 0.81
Local ablative treatments for hepatocellular carcinoma: An updated review. World J Gastrointest Pharmacol Ther (2016) 0.80
The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. World J Surg (2015) 0.79
Development and novel therapeutics in hepatocellular carcinoma: a review. Ther Clin Risk Manag (2016) 0.79
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol (2015) 0.79
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int (2017) 0.77
Severity of liver cirrhosis: a key role in the selection of surgical modality for Child-Pugh A hepatocellular carcinoma. World J Surg Oncol (2015) 0.76
Switching bipolar hepatic radiofrequency ablation using internally cooled wet electrodes: comparison with consecutive monopolar and switching monopolar modes. Br J Radiol (2015) 0.76
Surgical resection versus ablation for hepatocellular carcinoma ≤ 3 cm: a population-based analysis. HPB (Oxford) (2015) 0.76
Radiofrequency ablation versus surgical resection for small unifocal hepatocellular carcinomas. Medicine (Baltimore) (2014) 0.75
Novel implications in the treatment of hepatocellular carcinoma. Ann Gastroenterol (2016) 0.75
Switching Monopolar Radiofrequency Ablation Using a Separable Cluster Electrode in Patients with Hepatocellular Carcinoma: A Prospective Study. PLoS One (2016) 0.75
Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. Cancer Med (2017) 0.75
Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Dig Dis Sci (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology (2011) 4.60
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology (2005) 2.50
The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol (2009) 2.47
Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol (2012) 2.39
Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res (2010) 2.30
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2010) 2.28
The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol (2006) 2.27
Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg (2012) 2.27
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J Pathol (2012) 2.27
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int (2009) 2.27
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. J Hepatol (2013) 2.23
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int (2014) 2.23
Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology (2013) 2.16
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2009) 2.16
When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology (2015) 2.15
The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol (2005) 2.13
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl (2005) 2.04
Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg (2003) 2.03
Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol (2009) 2.02
MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med (2008) 1.99
Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol (2008) 1.98
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis (2013) 1.85
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res (2009) 1.84
Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol (2010) 1.76
Trends in perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected cases over 20 years. Ann Surg (2009) 1.73
Characterization of focal liver lesions with contrast-enhanced ultrasound. Ultrasound Med Biol (2010) 1.67
Surgery versus conservative antibiotic treatment in acute appendicitis: a systematic review and meta-analysis of randomized controlled trials. Dig Surg (2011) 1.67
Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation? Liver Transpl (2007) 1.61
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int (2013) 1.57
Liver AL amyloidosis as a possible cause of high liver stiffness values. Eur J Gastroenterol Hepatol (2010) 1.56
Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol (2012) 1.56
Role of hepatitis B virus infection in the prognosis after hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a Western dual-center experience. Arch Surg (2009) 1.53
Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology (2011) 1.50
Prognostic evaluation of the new American Joint Committee on Cancer/International Union Against Cancer staging system for hepatocellular carcinoma: analysis of 112 cirrhotic patients resected for hepatocellular carcinoma. Ann Surg Oncol (2005) 1.48
Classification of lymph node metastases from gastric cancer: comparison between N-site and N-number systems. Our experience and review of the literature. Am Surg (2007) 1.47
Use of vascular clamping in hepatic surgery: lessons learned from 1260 liver resections. Arch Surg (2008) 1.45
Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era. Transplantation (2006) 1.43
Guidelenines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society. World J Emerg Surg (2010) 1.39
Is portal hypertension a contraindication to hepatic resection? Ann Surg (2009) 1.34
Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg (2012) 1.34
Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl (2006) 1.31
Incidence of gallstone disease in Italy: results from a multicenter, population-based Italian study (the MICOL project). World J Gastroenterol (2008) 1.31
Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl (2005) 1.30
Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation (2004) 1.27
Intestinal and multivisceral transplantation. World J Surg (2001) 1.25
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology (2012) 1.23
Impact of biliary complications in right lobe living donor liver transplantation. Transpl Int (2006) 1.23
Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis. Eur Radiol (2011) 1.22
P.O.P.A. study: prevention of postoperative abdominal adhesions by icodextrin 4% solution after laparotomy for adhesive small bowel obstruction. A prospective randomized controlled trial. J Gastrointest Surg (2011) 1.22
Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl (2011) 1.22
Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. Cancer Res (2004) 1.21
Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. World J Gastroenterol (2009) 1.18
Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation (2011) 1.18
Acoustic Radiation Force Impulse elastography for fibrosis evaluation in patients with chronic hepatitis C: an international multicenter study. Eur J Radiol (2012) 1.18
Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int (2007) 1.15
Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol (2009) 1.14
The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. Ann Surg (2004) 1.14
Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med (2007) 1.14
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer (2013) 1.12
Is laparoscopic adrenalectomy safe and effective for adrenal masses larger than 7 cm? Surg Endosc (2007) 1.12
Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol (2008) 1.11
Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl (2008) 1.11
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer (2014) 1.11
Gastrointestinal stromal tumor of the anal canal: an unusual presentation. World J Surg Oncol (2007) 1.11
Bologna Guidelines for Diagnosis and Management of Adhesive Small Bowel Obstruction (ASBO): 2010 Evidence-Based Guidelines of the World Society of Emergency Surgery. World J Emerg Surg (2011) 1.11
Hepatic resection for primary or secondary malignancies with involvement of the inferior vena cava: is this operation safe or hazardous? J Am Coll Surg (2005) 1.11
Mutated beta-catenin evades a microRNA-dependent regulatory loop. Proc Natl Acad Sci U S A (2011) 1.08
A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. Ann Surg Oncol (2012) 1.07
Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol (2010) 1.06